Abstract 182P
Background
Combining LEN with anti-PD-1 antibodies (LEN+PD1) has shown promising anti-tumour effect against advanced HCC in KEYNOTE 524 and Study 117. We assessed LEN+PD1 vs LEN monotherapy in Chinese patients (Pts) with advanced HCC.
Methods
This real-world study included Pts with untreated advanced HCC who received lenvatinib (8 mg/d regardless of bodyweight) ± anti-PD-1 antibodies (q3wk) between Nov 2018 and Nov 2019, and had ≥1 efficacy and safety assessment. Endpoints included objective response rate (ORR), disease control rate (DCR) and progression free survival (PFS) evaluated using mRECIST and RECIST 1.1 every 2 months from treatment initiation, ALBI score and safety.
Results
The study included 22 patients who received LEN+PD1 and 22 who received LEN. For patients in the LEN+PD1 and LEN groups, median follow-up was 6.6 and 5.3 months, mean age was 54.8 and 53.2 years, 81.8 and 90.9% had BCLC stage C disease, and 72.7 and 68.1% were Child-Pugh A, respectively. ORR and DCR were numerically higher in the LEN+PD1 group vs the LEN group (Table) and median PFS was 12.1 (95% CI: 7.9, 16.2) vs 8.9 months (95% CI: 6.6, 11.2; HR=0.58; 95% CI: 0.17, 1.93), respectively. A similar proportion of patients in both groups decreased one ALBI level from baseline (p=0.9331). The most common AEs in the LEN+PD1 group were hypertension (22.7% [5]), decreased appetite (18.2% [4]) and ALT increase (13.6% [3]) and in the LEN group were ALT increase (31.8% [7]), proteinuria (18.2% [4]) and decreased appetite (18.2% [4]). No unexpected safety signals were observed. Table: 182P
n (%) | RECIST 1.1 | mRECIST | ||||
LEN + PD1 n=22 | LEN n =22 | p | LEN + PD1 n=22 | LEN n =22 | p | |
ORR | 10 (45.5) | 4 (18.2) | 0.052 | 11 (50.0) | 7 (31.8) | 0.220 |
DCR | 20 (90.9) | 17 (77.3) | 0.216 | 20 (90.9) | 17 (77.3) | 0.216 |
Complete response | 1 (4.5) | 0 | 0.204 | 3 (13.6) | 2 (9.1) | 0.526 |
Partial response | 9 (40.9) | 4 (18.2) | 8 (36.4) | 5 (22.7) | ||
Stable disease | 10 (45.5) | 13 (59.1) | 9 (40.9) | 10 (45.5) | ||
Progressive disease | 2 (9.1) | 5 (22.7) | 2 (9.1) | 5 (22.7) |
Conclusions
LEN ± anti-PD-1 antibodies was effective and well tolerated in first-line treatment of patients with advanced HCC. LEN+PD1 showed a trend towards higher ORR, DCR, and longer PFS vs LEN, with no increase in hepatotoxicity. However, further evaluation in randomized, prospective trials is required.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
224P - Associations of pre-existing cardiovascular disease (CVD) with treatment patterns and survival outcomes in patients with localized prostate cancer: A real-world, population-based study
Presenter: Atul Batra
Session: e-Poster Display Session
225P - Prostate cancer treatments and outcomes in the elderly: A retrospective analysis of an Australian real-world cohort
Presenter: Michael Fernando
Session: e-Poster Display Session
226P - Use of PSMA PET in metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Andrew Jensen
Session: e-Poster Display Session
227P - Phase II study of pembrolizumab (pembro) plus enzalutamide for enzalutamide (enza)-resistant metastatic castration-resistant prostate cancer (mCRPC): Cohorts (C) 4 and 5 update from KEYNOTE-199
Presenter: Ulka Vaishampayan
Session: e-Poster Display Session
228P - Symptoms and impacts of metastatic castration-resistant prostate cancer (mCRPC) among Japanese patients designated to receive Ra-223
Presenter: Hiroji Uemura
Session: e-Poster Display Session
229P - Expanding the role of supervised exercise on fatigue in prostate cancer patient receiving androgen deprivation therapy: A meta-analysis of randomized controlled trial
Presenter: Niwanda Yogiswara
Session: e-Poster Display Session
230P - Molecular profiling and clinical characteristics of Chinese patients with prostate cancer
Presenter: Ranlu Liu
Session: e-Poster Display Session
231P - Phase II study of pembrolizumab in docetaxel-pretreated patients with metastatic castration-resistant prostate cancer (mCRPC): Updated follow-up of cohorts (C) 1-3 from KEYNOTE-199
Presenter: Jeffrey Goh
Session: e-Poster Display Session
232P - Real-world data on metastatic castration-resistant prostate cancer patients treated with abiraterone or enzalutamide: A regional experience
Presenter: Rachel Raju
Session: e-Poster Display Session
243P - Target sequencing of 508 genes in Chinese epithelial ovarian cancer patients
Presenter: Li Lei
Session: e-Poster Display Session